Cumhur Tekin

410 total citations · 1 hit paper
15 papers, 224 citations indexed

About

Cumhur Tekin is a scholar working on Obstetrics and Gynecology, Oncology and Surgery. According to data from OpenAlex, Cumhur Tekin has authored 15 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Obstetrics and Gynecology, 11 papers in Oncology and 6 papers in Surgery. Recurrent topics in Cumhur Tekin's work include Endometrial and Cervical Cancer Treatments (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Colorectal and Anal Carcinomas (5 papers). Cumhur Tekin is often cited by papers focused on Endometrial and Cervical Cancer Treatments (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Colorectal and Anal Carcinomas (5 papers). Cumhur Tekin collaborates with scholars based in United States, Japan and Italy. Cumhur Tekin's co-authors include Kosei Hasegawa, Ronnie Shapira‐Frommer, Domenica Lorusso, Kan Li, Vanessa Samouëlian, Pamela Salman, Mivael Olivera, Vincent Castonguay, Coraline Dubot and Krishnansu S. Tewari and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Gynecologic Oncology.

In The Last Decade

Cumhur Tekin

14 papers receiving 223 citations

Hit Papers

First-Line Pembrolizumab + Chemotherapy Versus Placebo + ... 2023 2026 2024 2025 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
    2023 100 citations Bradley J. Monk, Nicoletta Colombo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cumhur Tekin United States 7 139 122 70 69 37 15 224
Mitchell Clark United States 9 52 0.4× 67 0.5× 35 0.5× 25 0.4× 16 0.4× 41 175
Lea Dutta United States 9 113 0.8× 89 0.7× 15 0.2× 31 0.4× 75 2.0× 26 214
Alfred Guirguis United States 9 68 0.5× 62 0.5× 25 0.4× 64 0.9× 41 1.1× 12 213
Ronaldo Lúcio Rangel Costa Brazil 8 45 0.3× 73 0.6× 44 0.6× 58 0.8× 21 0.6× 12 191
Hannah Donkers United Kingdom 8 48 0.3× 190 1.6× 38 0.5× 39 0.6× 19 0.5× 15 285
Carlos Bonilla Colombia 7 78 0.6× 21 0.2× 25 0.4× 17 0.2× 48 1.3× 29 158
Michelle Marcovitz United States 5 82 0.6× 44 0.4× 31 0.4× 68 1.0× 78 2.1× 6 162
Katrina Diamante Australia 2 83 0.6× 59 0.5× 41 0.6× 35 0.5× 65 1.8× 3 154
Karen Verhoeven-Adema Netherlands 3 51 0.4× 269 2.2× 50 0.7× 58 0.8× 30 0.8× 5 309
Petra Jankowska United Kingdom 4 34 0.2× 43 0.4× 34 0.5× 31 0.4× 24 0.6× 6 141

Countries citing papers authored by Cumhur Tekin

Since Specialization
Citations

This map shows the geographic impact of Cumhur Tekin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cumhur Tekin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cumhur Tekin more than expected).

Fields of papers citing papers by Cumhur Tekin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cumhur Tekin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cumhur Tekin. The network helps show where Cumhur Tekin may publish in the future.

Co-authorship network of co-authors of Cumhur Tekin

This figure shows the co-authorship network connecting the top 25 collaborators of Cumhur Tekin. A scholar is included among the top collaborators of Cumhur Tekin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cumhur Tekin. Cumhur Tekin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
3.
Tekin, Cumhur, et al.. (2024). Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer. Journal of Gynecologic Oncology. 35(6). e105–e105. 7 indexed citations
4.
5.
6.
Monk, Bradley J., Nicoletta Colombo, Krishnansu S. Tewari, et al.. (2023). First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. Journal of Clinical Oncology. 41(36). 5505–5511. 100 indexed citations breakdown →
7.
8.
Gokhale, Mugdha, Matthew Monberg, Cumhur Tekin, et al.. (2023). Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States. Cancer Treatment and Research Communications. 36. 100726–100726. 2 indexed citations
9.
10.
Tewari, Krishnansu S., Nicoletta Colombo, Bradley J. Monk, et al.. (2023). Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. JAMA Oncology. 10(2). 185–185. 21 indexed citations
11.
Monk, Bradley J., Nicoletta Colombo, Krishnansu S. Tewari, et al.. (2023). KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.. Journal of Clinical Oncology. 41(16_suppl). 5500–5500. 11 indexed citations
12.
Nishio, Shin, Kan Yonemori, Tomoka Usami, et al.. (2022). Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826. Cancer Science. 113(11). 3877–3887. 23 indexed citations
13.
Tewari, Krishnansu S., Nicoletta Colombo, Bradley J. Monk, et al.. (2022). Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.. Journal of Clinical Oncology. 40(16_suppl). 5506–5506. 9 indexed citations
14.
15.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mitchell Clark Breakdown of academic impact, for papers by Lea Dutta Breakdown of academic impact, for papers by Alfred Guirguis Breakdown of academic impact, for papers by Ronaldo Lúcio Rangel Costa Breakdown of academic impact, for papers by Hannah Donkers Breakdown of academic impact, for papers by Carlos Bonilla Breakdown of academic impact, for papers by Michelle Marcovitz Breakdown of academic impact, for papers by Katrina Diamante Breakdown of academic impact, for papers by Karen Verhoeven-Adema Breakdown of academic impact, for papers by Petra Jankowska
Rankless by CCL
2026